Gut-Liver Axis

Gut-Liver Axis, Bile Acids, and Microbiome (2025 Overview)

Bile acids are synthesized in the liver from cholesterol and then conjugated with glycine or taurine before being released into the small intestine. Their main role is to emulsify dietary fats and fat-soluble vitamins for absorption. After doing their work, most bile acids are reabsorbed in the terminal ileum and sent back to the liver, but about 5% reach the colon, where gut microbes transform them into secondary bile acids. These microbial conversions, performed by anaerobic bacteria such as Clostridium, involve enzymes like bile salt hydrolase and 7α-dehydroxylase. This process creates secondary bile acids such as deoxycholic acid and lithocholic acid, which differ in solubility and biological effects.

Not only do bile acids aid in digestion; they act as powerful signaling molecules within the body. Specialized receptors—most notably FXR (farnesoid X receptor) and TGR5—are distributed across the liver, intestines, immune cells, and brown fat. When activated, these receptors coordinate feedback regulation of bile acid synthesis, lipid and glucose metabolism, and anti-inflammatory mechanisms. FXR critically controls bile acid production and helps maintain the integrity of the intestinal barrier, while TGR5 influences energy expenditure and immune cell function. The balance and proportion of primary versus secondary bile acids shape the intensity and outcomes of these signals, impacting host metabolism and immune health.

Diet is a major driver in this system. High-fat, animal-based diets (especially those high in taurine) alter bile acid profiles and encourage the proliferation of the bacterium Bilophila wadsworthia, which is associated with inflammatory bowel disease and metabolic disorders. This microbe thrives on taurine-derived substrates and produces hydrogen sulfide that can damage the gut barrier and promote inflammation. Conversely, plant-rich diets with plenty of fiber support microbial diversity, protect against harmful bile acid concentrations, and foster the production of beneficial short-chain fatty acids.

Recent research emphasizes the importance of the gut-liver axis in metabolic, hepatic, and immune conditions such as NAFLD, diabetes, and inflammatory bowel disease. The modulation of the microbiome—through diet, prebiotics, probiotics, or targeted drugs influencing FXR and TGR5—is showing promise for therapeutic intervention. As of 2025, ongoing studies focus on individual variation in bile acid metabolism, rare bile acids, and disease links so these mechanisms may be leveraged for clinical benefit.

References: PubMed 39959949 (bile acid-microbiome in children/adults), PMC10337508 (FXR/TGR5 signaling), Quadram Institute (Bilophila and diet, June 2025), Nature Communications (high-fat diet and metabolic syndrome, 2018), Frontiers in Microbiology (global trends 2025).


Comments

Popular posts from this blog

Gemini

Sofia

Claude